e-ISSN 2147-2475

Hzl Arama




Laparoscopic Endoscopic Surgical Science Anti-TNF Ajan Kullanan Ankilozan Spondilitli ki Hastada COVID-19 Pnmonisi [Respir Case Rep]
Respir Case Rep. 2021; 10(2): 78-82 | DOI: 10.5505/respircase.2021.60565

Anti-TNF Ajan Kullanan Ankilozan Spondilitli ki Hastada COVID-19 Pnmonisi

dris Kurt1, Ebru akr Edis2, Habibe Tlin Elmaslar Mert3
1Trakya niversitesi Tp Fakltesi, Hastalklar Ana-bilim Dal, Edirne
2Trakya niversitesi Tp Fakltesi, Gs Hastalklar Anabilim Dal, Edirne
3Trakya niversitesi Tp Fakltesi, Klinik Mikrobiyoloji ve Enfeksiyon Hastalklar Anabilim Dal, Edirne

inde, Aralk 2019da grlmeye balanan yeni tip koronavirus (SARS-CoV2) hzla tm dnyaya yaylm ve kresel bir sorun haline gelmitir. Kardiyovaskler hastalk, hipertansiyon, diyabet gibi komorbiditesi olan kiilerde COVID-19 daha sk rastlanmakta ve daha ar seyretmektedir. Romatolojik hastalklarn ve bunlarn tedavisinde kullanlan ilalarn COVID-19 gelime riskini arttrp arttrmad tartmaldr. Literatrde zellikle Ankilozan Spondilitli hastalarda COVID-19 geliimi ile ilgili veri eksiklii mevcuttur. Biz bu olgu sunumunda Anti-TNF kullanrken, COVID-19 enfeksiyonu geiren, iki Ankilozan Spondilitliyi sunmay amaladk. Komorbiditesi olmayan gen hastamz, antiviral ve destek tedavisi ile hzl ekilde iyileti. Kronik kardiyovaskler ve bbrek hastal olan yal hastamzn seyri daha ar oldu ve hayat kayb ile sonuland. COVID-19 enfeksiyonun seyri ve mortalitesi, altta yatan komorbid hastalklar ile yakn ilikilidir. Ankilozan Spondilitli iki olgu rnei zerinden romatolojik hastalklar ve kullanlan immnsupresif tedavilerin yeni tip koronavirs enfeksiyonu seyrine etkisini, literatr eliinde, tartmay amaladk.

Anahtar Kelimeler: Ankilozan Spondilit, anti-TNF ajanlar, COVID-19.

COVID-19 Pneumonia in two Patients with Ankylosing Spondylitis Using Anti-TNF Agents

dris Kurt1, Ebru akr Edis2, Habibe Tlin Elmaslar Mert3
1Department of Internal Medicine, Trakya University Medical Faculty, Edirne, Turkey
2Department of Pulmonary Medicine, Trakya University Medical Faculty, Edirne, Turkey
3Department of Clinical Microbiology and Infection, Trakya University Medical Faculty, Edirne, Turkey

The new type of coronavirus (SARS-CoV2) reported to have originated in China in December 2019 has spread rapidly all over the world and has become a global problem. COVID-19 is more common and more severe in people with such comorbidities as cardiovascular disease, hypertension and diabetes. There is a lack of consensus on whether rheumatological diseases and drugs used in their treatment increase the risk of developing COVID-19. There is also lack of data in literature regarding the development of COVID-19, especially in patients with Ankylosing Spondylitis. This case presentation relates to two patients with Ankylosing Spondylitis using anti-TNF agents who were affected by COVID-19. The younger of the two, who had no comorbidities, healed quickly with antiviral and supportive therapy, while the older patient, who had cardiovascular and chronic kidney comorbidities, experienced an aggressive disease course and did not survive. The course of COVID-19 infection and mortality is strongly connected with underlying comorbidities. Our focus here is on rheumatological diseases, their immunosuppressive treatments and their impact on the course of the novel type Coronavirus infection, based on two cases of Ankylosing Spondylitis, in light of literature.

Keywords: Ankylosing Spondylitis, anti-TNF agents, COVID-19.

Olgunun Grnt Kesitleri

#1


#2




dris Kurt, Ebru akr Edis, Habibe Tlin Elmaslar Mert. COVID-19 Pneumonia in two Patients with Ankylosing Spondylitis Using Anti-TNF Agents. Respir Case Rep. 2021; 10(2): 78-82

Sorumlu Yazar: dris Kurt, Trkiye
LookUs & Online Makale